AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp. (AHCO) reported Q3 2025 results. Net revenue was $820.3 million versus $805.9 million a year ago. Operating income was $61.7 million, and net income attributable to AdaptHealth was $24.5 million, or diluted EPS of $0.16 (vs. $0.15). Segment revenue totaled $354.8 million in Sleep Health, $177.0 million in Respiratory Health, $150.1 million in Diabetes Health, and $138.4 million in Wellness at Home.
On the balance sheet, long‑term debt (less current) was $1.74 billion and cash was $80.4 million as of September 30, 2025. Year‑to‑date, operating cash flow was $418.6 million, with a $32.2 million pre‑tax gain from the sale of two businesses closed on May 1 and June 9, 2025. For the nine months, depreciation and amortization (including patient equipment) was $284.4 million. As of October 31, 2025, there were 135,424,334 common shares outstanding.
AdaptHealth Corp. furnished an update on its recent performance by issuing a press release with financial results for the quarter ended September 30, 2025. The company released these results on November 4, 2025 and attached the full press release as an exhibit to this report.
The disclosure is provided under the results of operations and financial condition section and is treated as “furnished” rather than “filed,” which limits certain legal liabilities. The press release is identified as Exhibit 99.1, with an additional exhibit covering the interactive data for the cover page.
David S. Williams III, a director of AdaptHealth Corp. (AHCO), sold 8,200 shares on 08/22/2025 at a weighted average price of $9.73 per share. The filing shows the reported sales occurred in multiple transactions at prices ranging from $9.60 to $9.85, and the reporting person continues to beneficially own 50,045 shares following the transactions. The Form 4 was filed by one reporting person and signed by an attorney-in-fact, with a previously filed power of attorney incorporated by reference.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.
AdaptHealth Corp. (AHCO) – Form 4 insider activity
Director Theodore B. Lundberg reported two acquisitions of AdaptHealth common stock on 06/26/2025:
- 21,346 shares acquired
- 7,864 shares acquired
Both transactions are recorded at $0, indicating they were equity grants or similar non-cash awards rather than open-market purchases. Following the transactions, Lundberg’s direct beneficial ownership rose to 859,756 shares. No dispositions, derivative securities, or 10b5-1 plan designations were disclosed, and the filing lists a Power of Attorney (Exhibit 24) supporting the submission.
The Form 4 contains no additional financial metrics or narrative commentary.